Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

The targeting of oncogenic 'driver' kinases with small molecule inhibitors has proven to be a highly effective therapeutic strategy in selected non-small cell lung cancer (NSCLC) patients. However, acquired resistance to targeted therapies invariably arises and is a major limitation to pat...

Full description

Bibliographic Details
Main Authors: Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan, D Ross Camidge, Marileila Varella-Garcia, Robert C Doebele
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3862576?pdf=render

Internet

http://europepmc.org/articles/PMC3862576?pdf=render

Similar Items